Stereochemistry | RACEMIC |
Molecular Formula | C16H19N3 |
Molecular Weight | 253.3422 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN2C(C1)C3=CC=CN3CC4=CC=CC=C24
InChI
InChIKey=MNHDDERDSNZCCK-UHFFFAOYSA-N
InChI=1S/C16H19N3/c1-17-9-10-19-14-6-3-2-5-13(14)11-18-8-4-7-15(18)16(19)12-17/h2-8,16H,9-12H2,1H3
Molecular Formula | C16H19N3 |
Molecular Weight | 253.3422 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Aptazapine is a “non-classic” tetracyclic antidepressant drug. Compound bears a structural resemblance to mianserin. Aptazapine possesses a high degree of potency and selectivity for central alpha-2, as opposed to alpha-1, adrenoceptors. Aptazapine failed to inhibit in vitro uptake of norepinephrine or serotonin to an appreciable extent. However, it exhibited a moderate ability to compete for 5-HT2 receptor binding in calf frontal cortex, as measured by displacement of 3H-spiroperidol. Another property apparently shared with other antidepressants is the ability of aptazapine to inhibit histamine-activated adenyl cyclase. As centrally acting alpha-2 adrenoceptor antagonists, aptazapine significantly suppressed cataplexy, a major symptom of narcolepsy, in Doberman pinschers.